E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Alzheimer's Disease Drugs"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (15 January 2010)

Special Issue Editor

Guest Editor
Prof. Dr. Pierre Vandel

Psychiatry and Medical Psychology Department, University Hospital of Besançon, France
E-Mail
Phone: +33 3 81 21 86 11
Fax: +33 3 81 21 82 29

Special Issue Information

Dear Colleagues,

One of the main purpose of Alzheimer disease treatment is to improve cognitive abilities- such as memory and thinking and also slow progression of the disease. Despite many promising research current treatments cannot cure or halt the disease, but can offer some people modest improvement in some symptoms.

Alzheimer’s disease drugs are coming from 2 main categories: drugs to treat cognitive symptoms and drugs to treat specific behavioral disturbances that do not respond to non-pharmacological behavioral-management approaches. Prevention treatment are also of some importance.

Research into Alzheimer’s is focused on different possible treatments such as increasing the efficiency of the damaged nerve cells, preventing production and inhibiting the build-up of beta amyloid proteins, protecting nerve cells from the damaging effects of hydrogen peroxide.

If cholinestérase inhibitors are the first drugs developped, recent progress have highlited other drugs with different targets such as amyloid plaques or neurofibrillary tangles. Alzheimer’s vaccine, secretase modulators, anti-inflammatory drugs or even some antibiotics have been tested and seem to interfere with the development of amyloid plaques in the brain. Countless new treatments are in development, so more options will be available in the near future.

The purpose of this special issue is to assess the current status of AD drugs and perspective of new treatment stratégies through comprehensive reviews or original research datas.

Prof. Dr. Pierre Vandel
Guest Editor

Keywords

  • alzheimer disease
  • cognitive behavior disorder
  • memory
  • beta amyloid
  • antioxydants
  • cholinesterase inhibitors
  • vaccine
  • prevention

Published Papers (2 papers)

View options order results:
result details:
Displaying articles 1-2
Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer's Disease and Related Disorders
Pharmaceuticals 2010, 3(8), 2387-2397; doi:10.3390/ph3082387
Received: 2 June 2010 / Revised: 21 June 2010 / Accepted: 20 July 2010 / Published: 26 July 2010
Cited by 2 | PDF Full-text (182 KB) | HTML Full-text | XML Full-text
Abstract
Behavioral and psychological symptoms (BPSD) are now known to be frequently associated to cognitive and functional decline in Alzheimer‘s disease and related disorders. They are present since the early stages of the disease and have negative impact on the disease process. BPSD assessment
[...] Read more.
Behavioral and psychological symptoms (BPSD) are now known to be frequently associated to cognitive and functional decline in Alzheimer‘s disease and related disorders. They are present since the early stages of the disease and have negative impact on the disease process. BPSD assessment is crucial in clinical practice and also in future clinical trials targeting disease-modifying therapies for dementia. In this article, we will first review current assessment tools for BPSD, mainly global and domain-specific scales, and new assessment methods, currently available or in development, including new scales, diagnostic criteria and new technologies such as ambulatory actigraphy. Full article
(This article belongs to the Special Issue Alzheimer's Disease Drugs)

Review

Jump to: Research

Open AccessReview Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants
Pharmaceuticals 2010, 3(10), 3040-3100; doi:10.3390/ph3103040
Received: 28 May 2010 / Revised: 7 September 2010 / Accepted: 25 September 2010 / Published: 29 September 2010
Cited by 11 | PDF Full-text (524 KB) | HTML Full-text | XML Full-text
Abstract
About 80% of functional genes in the human genome are expressed in the brain and over 1,200 different genes have been associated with the pathogenesis of CNS disorders and dementia. Pharmacogenetic studies of psychotropic drug response have focused on determining the relationship between
[...] Read more.
About 80% of functional genes in the human genome are expressed in the brain and over 1,200 different genes have been associated with the pathogenesis of CNS disorders and dementia. Pharmacogenetic studies of psychotropic drug response have focused on determining the relationship between variations in specific candidate genes and the positive and adverse effects of drug treatment. Approximately, 18% of neuroleptics are substrates of CYP1A2 enzymes, 40% of CYP2D6, and 23% of CYP3A4; 24% of antidepressants are substrates of CYP1A2 enzymes, 5% of CYP2B6, 38% of CYP2C19, 85% of CYP2D6, and 38% of CYP3A4; 7% of benzodiazepines are substrates of CYP2C19 enzymes, 20% of CYP2D6, and 95% of CYP3A4. 10-20% of Western populations are defective in genes of the CYP superfamily; and the pharmacogenomic response of psychotropic drugs also depends on genetic variants associated with dementia. Prospective studies with anti-dementia drugs or with multifactorial strategies have revealed that the therapeutic response to conventional drugs in Alzheimer’s disease is genotype-specific. The disease-modifying effects (cognitive performance, biomarker modification) of therapeutic intervention are APOE-dependent, with APOE-4 carriers acting as the worst responders (APOE-3/3 > APOE-3/4 > APOE-4/4). APOE-CYP2D6 interactions also influence the therapeutic outcome in patients with dementia. Full article
(This article belongs to the Special Issue Alzheimer's Disease Drugs)

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.


Journal Contact

MDPI AG
Pharmaceuticals Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
pharmaceuticals@mdpi.com
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Pharmaceuticals
Back to Top